Pterostilbene for Health & Longevity

Evidence Review created on 09/29/2026 using AI4L / Opus 5.5

Also known as: trans-Pterostilbene, PTS, Resveratrol Dimethyl Ether, 3,5-dimethoxy-4’-hydroxystilbene, pTeroPure, Silbinol

Motivation

Pterostilbene is a plant compound found in small amounts in blueberries, grapes and the heartwood of the Indian kino tree. It is a close chemical cousin of resveratrol, the red-wine compound once widely promoted for healthy aging, but a slightly different structure makes it more fat-soluble, which raises the question of whether the body absorbs it better. That possible absorption advantage is the main reason it attracts interest as a possible successor to resveratrol.

Research interest grew from laboratory and animal studies of how the compound influences the body’s stress-defense and energy-sensing systems, and of its possible relevance to brain aging, cholesterol and blood pressure. It is sold both as a stand-alone supplement and, more prominently, as the partner ingredient in a popular product that pairs it with a form of vitamin B3. Much of the human research has been funded or supplied by companies that sell these products.

This review examines what human trials, animal research and studies of how the body absorbs and clears the compound show about the benefits and risks of pterostilbene for health-focused adults, how it is dosed and combined, how its effects can be tracked, and where the evidence remains incomplete.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Pterostilbene

An AI-generated encyclopedia entry covering chemistry, dietary sources, bioavailability relative to resveratrol, research areas and regulatory status; useful orientation, though its claims need checking against the primary studies.

Examine

Pterostilbene benefits, dosage, and side effects

Evidence-graded summary by Bill Willis, PhD, stressing how sparse human research is and highlighting the cholesterol increase seen in the only dedicated metabolic trial, alongside dosing and resveratrol comparisons.

ConsumerLab

No dedicated ConsumerLab article on pterostilbene exists. The compound is mentioned only within member-only reviews of resveratrol supplements and of nicotinamide riboside products.

Systematic Reviews

The only meta-analysis of pterostilbene on PubMed, limited to preclinical research.

The effect of pterostilbene and its active ingredients on experimental pulmonary fibrosis in asthma: a meta-analysis. - Peng et al., 2022

Pools seven controlled animal experiments; pterostilbene raised antioxidant enzymes and lowered oxidative-damage markers. No human data were included.

No systematic review or meta-analysis covers pterostilbene’s human benefits or its principal risk, the rise in cholesterol seen in trials; both the claimed effects and the principal risk are unrepresented.

Mechanism of Action

Pterostilbene is resveratrol with two of its three hydroxyl (–OH) groups capped by methyl groups, making it more fat-soluble and more slowly cleared. Proposed pathways:

Stress defense: activates Nrf2 (nuclear factor erythroid 2–related factor 2, a master switch for antioxidant genes) in animal models (Xu 2021).
Energy sensing: activates AMPK (the cell’s fuel gauge, shifting metabolism toward fat burning) and curbs liver-cell glucose output (Ren 2018).
Lipid regulation: activates PPARα (peroxisome proliferator-activated receptor alpha, the fat-burning switch targeted by fibrate triglyceride-lowering drugs) (Rimando 2005).
Inflammation: blocks COX-2 (cyclooxygenase-2, an enzyme making inflammatory prostaglandins) in laboratory tests, but oral extract gave volunteers blood levels too low to do so (Hougee 2005).
Sirtuins: marketed as a SIRT1 activator (sirtuin 1, a stress-resistance enzyme fueled by NAD+), yet in aging mice its memory benefit tracked PPARα, not SIRT1 (Chang 2012).

Rat oral bioavailability (the share of a dose reaching the bloodstream) is 16–80% by formulation, versus 20% for resveratrol (Kapetanovic 2011; Yeo 2013); rat elimination half-life is 1.5–1.8 hours; human values are unpublished. It concentrates in liver; brain tissue holds mostly unchanged compound (Azzolini 2014). Clearance is by sulfate and glucuronide attachment (glucuronidation), the latter mainly via UGT1A1 and UGT1A3 (liver enzymes tagging compounds for excretion) (Dellinger 2014). Selectivity is low; it inhibits CYP2C9 (a liver enzyme clearing warfarin and NSAIDs, non-steroidal anti-inflammatory drugs) (Albassam 2021) and UGT1A9 (a glucuronidation enzyme clearing the transplant drug mycophenolic acid) (Jiang 2020).

Historical Context & Evolution

The heartwood of the Indian kino tree (Pterocarpus marsupium), known in Ayurveda as Vijayasar and rich in pterostilbene, was traditionally used for diabetes, and an uncontrolled trial of the extract reported lower blood sugar in newly diagnosed type 2 diabetes (ICMR 1998). Plant scientists later identified pterostilbene in grapevines as a phytoalexin (a defensive compound plants make against fungal infection).

Health interest came with the resveratrol wave of the 2000s. U.S. Department of Agriculture chemist Agnes Rimando showed it activated PPARα more strongly than resveratrol and lowered cholesterol in hamsters (Rimando 2005), aged rats fed it improved working memory (Joseph 2008), and roughly fourfold higher bioavailability in rats (Kapetanovic 2011) led to marketing as a “better resveratrol”.

ChromaDex then introduced its pTeroPure ingredient and supplied all materials for the first dedicated RCT (randomized controlled trial), which found lower blood pressure but an unexpected rise in LDL (low-density lipoprotein, “bad”) cholesterol (Riche 2014). In 2015 Elysium Health, co-founded by sirtuin researcher Leonard Guarente, launched NRPT (nicotinamide riboside, a vitamin B3 form, plus pterostilbene) as Basis and has funded most later trials, including EH301 in ALS (amyotrophic lateral sclerosis, a fatal motor-neuron disease) (de la Rubia 2019).

The LDL finding, and animal work showing benefits without sirtuin activation, shifted opinion from “sirtuin activator” toward a multi-target compound whose human value is still being tested; company-funded combination trials with positive signals keep the question open.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the only placebo-controlled clinical outcome for pterostilbene alone is blood pressure in a single 80-person trial, and the larger human trials tested it only combined with nicotinamide riboside.

Medium 🟩 🟩

Blood Pressure Reduction

In the ChromaDex-supplied RCT of 80 adults with hypercholesterolemia (high blood cholesterol), 125 mg twice daily for 6–8 weeks lowered systolic and diastolic pressure; among pterostilbene-only arms the effect was confined to that higher dose, though 50 mg twice daily plus grape extract also lowered systolic pressure (Riche 2014). The mechanism is unclear; the authors noted a resemblance to PPAR-activating drugs. A Sabinsa-funded extract trial (200 mg/day) in healthy, normal-pressure adults found no change (Majeed 2023), consistent with larger effects when starting pressure is higher.

Magnitude: −7.8 mmHg systolic and −7.3 mmHg diastolic versus placebo at 250 mg/day over 6–8 weeks.

Low 🟩

Liver Enzyme Improvement

In an Elysium-funded 6-month RCT of 111 adults with NAFLD (non-alcoholic fatty liver disease), standard-dose NRPT lowered ALT and GGT (liver-injury enzymes), but double dose did not, and liver fat was unchanged (Dellinger 2023). ALT also fell in healthy older adults. Pterostilbene’s own share cannot be isolated.

Magnitude: In an Elysium-funded trial of healthy older adults, ALT fell by a mean 1.9 U/L over 60 days on standard-dose NRPT versus a 1.6 U/L rise on placebo (Dellinger 2017).

Menopause-Transition Symptom Relief

An Elysium-authored, open-label 7-day pilot gave standard-dose NRPT to 40 women; the 32 with menopause-transition symptoms reported fewer and milder hot flashes, bloating and poor sleep (Holmes 2026). There was no placebo arm, and the combination, not pterostilbene alone, was tested.

Magnitude: 75% reported less frequent hot flashes, 84% less frequent poor sleep and 78% less frequent bloating after 7 days (uncontrolled, within-group).

Slower ALS Progression ⭕️ Not Central to Health & Longevity

In an Elysium-supported, 4-month pilot RCT of 32 people with ALS, EH301 slowed decline in function score, lung capacity and strength versus placebo (de la Rubia 2019). The combination was tested, not pterostilbene alone. This bears on treating a neurodegenerative disease, not on healthy longevity.

Magnitude: Function score (ALSFRS-R, the standard ALS disability scale) rose 2.5 points on EH301 versus a 5.5-point fall on placebo over 4 months among the 20 completers.

Modest Weight Reduction

In the ChromaDex-supplied RCT, participants not taking cholesterol medication (51 of 80) showed a small drop in body mass index on pterostilbene (Riche 2014). This came from a subgroup analysis; overall the compound was weight-neutral.

Magnitude: −0.62 kg/m² in body mass index over 6–8 weeks in the subgroup not on cholesterol medication.

Blood Sugar Control

An uncontrolled 12-week trial of Pterocarpus marsupium extract, which contains pterostilbene among other compounds, lowered glucose in 97 people with new type 2 diabetes (ICMR 1998). Diabetic-rat data agree (Pari 2006), but pure-pterostilbene human trials saw no glucose change.

Magnitude: Fasting glucose fell 32 mg/dL and HbA1c (glycated hemoglobin, a 3-month blood-sugar average) from 9.8% to 9.4% at 12 weeks on 2–4 g/day of extract.

Speculative 🟨

Cognitive Protection in Aging

Aged rats fed pterostilbene improved working memory (Joseph 2008), and accelerated-aging mice improved maze performance where resveratrol did not (Chang 2012). No human cognitive trial exists; the basis is animal-only.

Lifespan Extension

Pterostilbene extended mean lifespan in both male and female fruit flies (Beghelli 2022). No mammalian lifespan study has been published, so the basis is invertebrate data only.

Cancer Prevention

Cell and rodent studies show tumor-growth inhibition. In the only randomized human test, 100 mg twice daily added to megestrol (a synthetic progesterone-like hormone drug) did not lower endometrial tumor Ki-67 (a cell-proliferation marker) (NCT03671811).

Cellular Energy and Sirtuin Support

NRPT raised whole-blood NAD+ by about 40% (standard dose) and 90% (double dose), likely via nicotinamide riboside (Dellinger 2017). Blood NAD+ is unvalidated, and an Elysium-co-authored trial found no muscle-repair benefit (Jensen 2022).

Inflammation and Immune Balance

In cell culture and colitis mice, pterostilbene shifted T cells toward anti-inflammatory regulatory cells and reduced colonic inflammation (Yashiro 2020). Human inflammation data are absent; the basis is laboratory and animal work.

Anxiety Reduction

Low oral doses (1–2 mg/kg) reduced anxiety-like behavior in mice, while higher doses did not (Al Rahim 2013). No human mood data exist; the basis is animal-only.

Skin Protection from Sun Damage

A scoping review found only early cell and animal evidence of protection from ultraviolet damage (Muralitharan 2025); in an Elysium-co-authored mouse study, NRPT reduced ultraviolet-induced skin swelling (Isak 2024). No human skin trials exist.

Benefit-Modifying Factors

Genetic polymorphisms: No genotype-based benefit studies exist. Variants lowering UGT1A1 activity, such as UGT1A1*28 (the cause of Gilbert syndrome, a harmless bilirubin elevation), may slow pterostilbene clearance and raise exposure, based on enzyme studies (Dellinger 2014).
Baseline blood pressure: The pressure fall scaled with starting pressure; the trial’s modeled change reached zero near 114/70 mmHg, so little reduction is expected in people already at optimal pressure (Riche 2014).
Baseline liver enzymes and NAD+: ALT fell both in fatty liver and in healthy older adults with normal baseline values. In an Elysium-co-authored trial of kidney-injury patients, whose blood NAD+ halved, NRPT raised levels (Simic 2020), suggesting larger effects where NAD+ is depleted.
Sex: Female liver tissue clears pterostilbene by glucuronidation more efficiently than male tissue (Dellinger 2014), possibly lowering exposure in women; fruit-fly lifespan gains were larger in females. Human sex-specific benefit data are absent.
Pre-existing conditions: Human signals come from high cholesterol with raised blood pressure, fatty liver disease, ALS, menopause-transition symptoms and, for the whole-plant extract only, new type 2 diabetes; healthy normal-pressure adults showed no change in a 2-month extract trial (Majeed 2023).
Age: NRPT was tested in adults aged 55–80 without safety concerns (Jensen 2022), and animal memory benefits appeared in aged animals. No human trial has analyzed benefit by age.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: adverse-event and lipid data for pterostilbene alone come from one hypercholesterolemic trial, one small open-label cancer trial and a few small safety studies, none longer than 12 weeks.

Medium 🟥 🟥

LDL Cholesterol Increase

In the ChromaDex-supplied RCT, pterostilbene alone raised LDL in adults with high cholesterol, and 250 mg/day lowered HDL (high-density lipoprotein, “good” cholesterol) in unmedicated participants; the LDL rise was absent with added grape extract and blunted with cholesterol-lowering medication (Riche 2014). An Elysium RCT saw dose-dependent LDL rises on NRPT, though baseline imbalance complicates it (Dellinger 2017); ChromaDex-affiliated authors, whose company sells nicotinamide riboside without pterostilbene, highlighted both (Brenner & Boileau 2019). A Sabinsa extract trial in normal-cholesterol adults found no change (Majeed 2023). Mechanism is unknown.

Magnitude: +17.1 mg/dL LDL versus placebo on pterostilbene alone; +0.48 mmol/L (about 19 mg/dL) within-group at 100 mg pterostilbene plus 500 mg nicotinamide riboside over 60 days, versus +0.10 mmol/L on placebo.

Gastrointestinal Discomfort

In an open-label randomized cancer trial, nausea affected 10 of 19 on pterostilbene plus megestrol versus 1 of 18 on megestrol alone (NCT03671811). Nausea, dyspepsia (indigestion) and diarrhea also occurred in NRPT trials, mostly at double dose (Dellinger 2017); 3 of 20 kidney-injury patients reported minor digestive effects (Simic 2020).

Magnitude: Nausea in 53% on pterostilbene plus megestrol versus 6% on megestrol alone over 3 weeks (open-label); treatment-related adverse events in 12.5% on double-dose NRPT versus 2.5% on placebo (not statistically significant).

Low 🟥

Increased Appetite and Weight Gain

In the ChromaDex-supplied safety analysis, four pterostilbene recipients reported increased appetite and gained weight (Riche 2013); the authors linked this to possible activation of PPAR-γ (the receptor targeted by glitazone diabetes drugs) (Riche 2014). This is an uncontrolled observation.

Magnitude: Four participants; mean gain 1.7 lb (0.8 kg) over 6–8 weeks.

Speculative 🟨

Drug Interactions via Liver-Enzyme Inhibition

In human liver tissue, pterostilbene strongly inhibited CYP2C9 (Albassam 2021) and UGT1A9; modeling predicts ≥50% higher exposure to UGT1A9-cleared drugs at ≥100 mg/day (Jiang 2020). No human interaction study exists.

Excess Blood Pressure Lowering with Antihypertensives

Because 250 mg/day lowered pressure by about 8 mmHg (Riche 2014), adding it to antihypertensives (blood-pressure drugs) could cause orthostatic hypotension (a pressure drop on standing). None has been reported; the basis is extrapolation.

Low Blood Sugar with Diabetes Drugs

Rat studies show glucose lowering comparable to metformin (Pari 2006); combined with insulin, this could theoretically cause hypoglycemia (abnormally low blood sugar). Pure-pterostilbene human trials saw no glucose change.

Hormone-Sensitive Tissue Effects

Pterostilbene acts through estrogen-receptor signaling in cell studies (Song 2015), and NRPT raised the estradiol-to-estrone ratio in women (Holmes 2026). Relevance to hormone-sensitive conditions is unknown; the basis is mechanistic only.

Risk-Modifying Factors

Genetic polymorphisms: CYP2C9*2 or *3 carriers already clear warfarin slowly, so added CYP2C9 inhibition could compound bleeding risk; UGT1A1*28 carriers may accumulate pterostilbene. Both risks are extrapolated from enzyme data.
Baseline LDL and lipid medication: LDL rose in hypercholesterolemic adults off cholesterol-lowering medication and was blunted in medicated ones (Riche 2014); people with high baseline LDL or ApoB (apolipoprotein B, a count of artery-clogging particles) carry the most lipid risk.
Sex: Trial cohorts were 68–71% women (Dellinger 2017; Riche 2013), so risk data mostly reflect women; faster female glucuronidation may lower exposure. No sex-specific adverse-event differences have been reported.
Pre-existing conditions: Atherosclerotic cardiovascular disease (artery-plaque disease), familial hypercholesterolemia (inherited very high LDL), low blood pressure, diabetes on glucose-lowering drugs and use of anticoagulants (blood thinners) raise the stakes of pterostilbene’s lipid, pressure and enzyme effects.
Age: Older adults more often take CYP2C9-cleared drugs and antihypertensives, raising interaction and dizziness risk; NRPT was nonetheless well tolerated in adults aged 60–80 over 8 weeks (Dellinger 2017).

Key Interactions & Contraindications

CYP2C9-cleared drugs (warfarin, phenytoin, glipizide, losartan): Caution. Enzyme inhibition may raise drug levels, causing bleeding with warfarin, toxicity with phenytoin or low blood sugar with glipizide. Mitigation: INR (international normalized ratio, a clotting-time test) or drug-level checks 1–2 weeks after starting.
UGT1A9-cleared drugs (mycophenolic acid, propofol, entacapone): Caution. A predicted ≥50% exposure increase at ≥100 mg/day could intensify effects, including immunosuppressant toxicity (Jiang 2020). Mitigation: avoiding the combination unless drug levels are monitored.
Antihypertensives (lisinopril, amlodipine, hydrochlorothiazide): Monitor. Additive pressure lowering could cause dizziness or fainting. Mitigation: home blood-pressure checks during the first 2–4 weeks; readings below 100/60 mmHg prompt review of the combination.
Statins and other lipid-lowering drugs (atorvastatin, rosuvastatin, ezetimibe): Monitor. Pterostilbene’s LDL rise may partly offset lipid therapy, although users of cholesterol-lowering medication showed blunted rises. Mitigation: a lipid panel 6–8 weeks after starting.
Glucose-lowering drugs (insulin, glipizide, glyburide): Monitor. Animal data suggest additive glucose lowering with hypoglycemia risk, compounded for glipizide by CYP2C9 inhibition. Mitigation: extra glucose checks during the first 2 weeks.
Over-the-counter NSAIDs (ibuprofen, naproxen): Caution. Both are cleared by CYP2C9; higher levels could increase gastrointestinal bleeding or kidney injury risk. Mitigation: lowest effective dose and short courses.
Over-the-counter acetaminophen (paracetamol): Monitor. It is cleared partly by UGT1A6 (another glucuronidation enzyme) and UGT1A9, both inhibited in laboratory tests (Jiang 2020); slower clearance could raise exposure and liver-injury risk, though clinical relevance is unknown. Mitigation: keeping total intake at or below 3 g/day.
Resveratrol and other stilbene (resveratrol-family plant compound) supplements: Monitor. Shared targets make effects overlapping or redundant, and combined lipid effects are untested. Mitigation: a lipid panel when combining them.
Nicotinamide riboside: No harmful interaction identified; the NRPT pairing was tolerated up to 1,000 mg nicotinamide riboside plus 200 mg pterostilbene twice daily for 2 days (Simic 2020). Severity: none; standard monitoring.
Grape extract: Favorable interaction, severity none: 100 mg twice daily prevented the LDL rise seen with pterostilbene alone in one trial arm (Riche 2014), although replication is lacking.
Blood-pressure- or glucose-lowering supplements (garlic, beetroot nitrate, berberine, chromium): Monitor. Additive lowering of pressure or glucose is plausible. Mitigation: home monitoring when combining.
Surgery and anesthesia: Caution. Propofol is cleared by UGT1A9, so inhibition could prolong its effects. Mitigation: stopping pterostilbene 3–7 days before elective surgery, a precautionary window.

Populations who should avoid Pterostilbene:

Pregnant or breastfeeding women (no safety data)
Children and adolescents under 18 years (no safety data)
People with LDL ≥190 mg/dL, familial hypercholesterolemia or established atherosclerotic cardiovascular disease whose lipids are not being monitored
People taking warfarin or phenytoin without INR or drug-level monitoring
Organ transplant recipients taking mycophenolic acid
People with symptomatic low blood pressure or resting readings below 90/60 mmHg

Risk Mitigation Strategies

Lipid panel before and after starting: Measuring LDL and ApoB at baseline and 6–8 weeks detects the LDL rise seen at 100–250 mg/day; a rise above 10% from baseline signals the lipid risk.
Low starting dose: Starting at 50 mg/day, the NRPT standard dose with smaller LDL changes, before any increase to 100–250 mg/day limits LDL-raising exposure while lipids are rechecked.
Grape extract co-administration: 100 mg grape extract twice daily with 50 mg pterostilbene twice daily prevented the LDL rise in one trial arm (Riche 2014), mitigating lipid risk, although replication is lacking.
Taking with a meal: Dosing with breakfast, as in NRPT trials, may reduce nausea and indigestion and aids absorption of this fat-soluble compound.
Interaction screening: Reviewing medications for drugs cleared by CYP2C9 and UGT1A9 before starting prevents unrecognized drug-level increases; INR checks 1–2 weeks after starting in warfarin users mitigate bleeding risk.
Home blood-pressure monitoring: For people on antihypertensives, twice-daily readings for 2 weeks detect additive lowering; readings below 100/60 mmHg or dizziness on standing flag excess pressure lowering.
Glucose checks with diabetes drugs: Extra fingerstick or continuous-glucose readings during the first 2 weeks guard against hypoglycemia when pterostilbene is combined with insulin or glipizide.
Pre-surgical pause: Stopping 3–7 days before elective surgery avoids a theoretical propofol interaction through UGT1A9 inhibition.
Third-party-tested product: Choosing products verified for identity and dose by USP (United States Pharmacopeia), NSF (NSF International) or ConsumerLab keeps intake at the labeled dose, limiting the dose-dependent LDL rise and excess blood-pressure lowering.

Therapeutic Protocol

Standard single-agent dose: 50–250 mg/day of trans-pterostilbene, the range tested in human trials; commercial products, many using ChromaDex’s pTeroPure ingredient, typically supply 50–100 mg. Pterostilbene alone lowered blood pressure only at 250 mg/day (Riche 2014).
Combination with an NAD+ precursor: Elysium Health’s Basis, co-founded by Leonard Guarente, pairs 50 mg pterostilbene with 250 mg nicotinamide riboside daily; 100 mg with 500 mg is the tested double dose (Dellinger 2017).
Pairing with resveratrol: Life Extension, which sells both pterostilbene and resveratrol products, promotes combining them on the premise of complementary gene effects; this approach has no human outcome trial.
Botanical-extract approach: Sabinsa’s Silbinol, a Pterocarpus marsupium extract standardized to 90% pterostilbene, was taken at 100 mg twice daily in its safety trial (Majeed 2023), echoing Ayurvedic use of the heartwood.
Time of day: NRPT trials used morning dosing with breakfast; no study compares timing. A fat-containing meal suits its fat solubility, and fasting cut bioavailability in rats (Yeo 2013).
Half-life: No human half-life has been published; in rats elimination half-life is about 1.5–1.8 hours (Azzolini 2014), so blood levels likely fall within hours of a dose.
Single versus split dosing: The blood-pressure (Riche 2014) and extract safety (Majeed 2023) trials used twice-daily dosing; NRPT trials used once daily. A short rodent half-life favors split dosing for steadier exposure, though no head-to-head comparison exists.
Genetic polymorphisms: No genotype-guided dosing exists. CYP2C9 poor metabolizers taking warfarin and UGT1A1*28 carriers are logical candidates for a 50 mg/day start and closer monitoring.
Sex: No sex-specific dosing data exist; women dominated trial cohorts, and faster female glucuronidation could modestly lower exposure. Menopause data came from the 50 mg NRPT dose.
Age: Adults aged 60–80 tolerated up to 100 mg/day in NRPT trials (Dellinger 2017); frequent multi-drug use in this group favors a 50 mg/day start with an interaction review.
Baseline biomarkers: Higher baseline blood pressure predicts greater pressure reduction, while elevated LDL or ApoB predicts greater lipid risk, favoring lower doses or grape-extract pairing and early lipid retesting.
Pre-existing conditions: The pressure-lowering dose, 250 mg/day, was tested in adults with high cholesterol; people with cardiovascular disease generally stay at the lower end, and fatty-liver data exist only for NRPT.

Discontinuation & Cycling

Duration: Pterostilbene is used as an open-ended daily supplement, not a short course; the longest published human exposure is about 1 year (EH301 open-label extension in ALS; de la Rubia 2019), so lifelong use is untested.
Withdrawal effects: None reported in any trial, including the 30-day post-treatment follow-up of the first NRPT trial (Dellinger 2017).
Tapering: Not required; no dependence or rebound mechanism is known, and trials stopped the compound abruptly.
Cycling: No study tests cycling for efficacy, and no tolerance has been shown. Some users cycle off to recheck lipids, which clarifies whether an LDL rise is pterostilbene-related.
Reversibility of lipid effects: If LDL rises, a recheck 4–6 weeks after stopping shows whether levels return to baseline; reversal has not been formally documented.

Sourcing and Quality

Synthetic trans-pterostilbene: Most supplements use nature-identical synthetic trans-pterostilbene of ≥99% purity, such as ChromaDex’s pTeroPure, the form used in the blood-pressure and LDL trial (Riche 2014).
Botanical extract: Pterocarpus marsupium heartwood extracts (e.g., Sabinsa’s Silbinol, ≥90% pterostilbene) carry minor co-extracted compounds; “blueberry pterostilbene” labels may deliver negligible amounts.
Enhanced-solubility forms: Cocrystals (crystals pairing the compound with a harmless partner molecule), such as a pterostilbene–picolinic acid cocrystal (Barbas 2022), aim to improve solubility; a cocrystal was compared with the free form in small human bioavailability studies (NCT05561075).
Isomer and stability: The studied trans isomer (a variant with the same atoms arranged differently) can convert to the cis isomer in light, so opaque, sealed packaging protects potency.
Third-party testing: Certificates of analysis confirming identity by HPLC (high-performance liquid chromatography, a laboratory separation test), purity, heavy metals and residual solvents, or USP, NSF or ConsumerLab seals, address mislabeling.
Reputable brands: Life Extension (pterostilbene products using pTeroPure), Elysium Health (Basis) and Sabinsa (Silbinol ingredient) supply the forms used in published research.

Practical Considerations

Time to effect: Blood-pressure changes appeared within 6–8 weeks (Riche 2014), blood NAD+ rose within 4 weeks on NRPT (Dellinger 2017), and menopause-symptom reports changed within 7 days (Holmes 2026); liver-enzyme effects emerged over months (Dellinger 2023).
Common pitfalls: Assuming “better absorbed than resveratrol” means proven benefit, skipping lipid checks, relying on blueberries (nanogram amounts per berry) for meaningful doses, and attributing NRPT results to pterostilbene alone.
Regulatory status: Sold in the U.S. as a dietary supplement; ChromaDex’s pTeroPure holds self-affirmed GRAS (generally recognized as safe) status (2011), set by an expert panel rather than FDA (U.S. Food and Drug Administration) review. EH301 is an investigational ALS therapy.
Cost and accessibility: Inexpensive and widely available; single-ingredient products usually cost well under US$1 per daily dose, while branded NRPT costs more. Insurers do not cover it, so no payer has a stake in its adoption.
Research funding context: Most human trials were supplied or funded by companies selling pterostilbene or NRPT (ChromaDex, Elysium Health, Sabinsa, Kewpie), and no large independent trial exists.

Interaction with Foundational Habits

Sleep: Indirect, possibly favorable. In an uncontrolled 7-day NRPT study, symptomatic menopausal women reported less frequent poor sleep (Holmes 2026); no data show sleep disruption. The mechanism is unknown, possibly estrogen balance. Morning dosing, as in trials, avoids any theoretical evening effect.
Nutrition: Direct, potentiating absorption. As a fat-soluble compound it suits a fat-containing meal; fasting reduced bioavailability in rats (Yeo 2013). Blueberries, grapes and almonds supply only trace amounts. No nutrient depletion is known, and grape extract blunted the LDL rise.
Exercise: None shown; blunting possible. NRPT did not improve muscle regeneration after injury in older adults (Jensen 2022). Resveratrol blunted training benefits in older men (Gliemann 2013), untested for pterostilbene; dosing away from training sessions is a precautionary option.
Stress management: Indirect, speculative. Low doses reduced anxiety-like behavior in mice through hippocampal ERK (extracellular signal-regulated kinase, a cell-signaling enzyme) changes (Al Rahim 2013); no human cortisol or mood data exist, and it does not replace behavioral stress management.

Monitoring Protocol & Defining Success

Before starting, a baseline panel sets reference points for pterostilbene’s known effects: a fasting lipid panel with ApoB, blood pressure averaged over one week of seated home readings, liver enzymes (ALT, GGT), fasting glucose and HbA1c, and an INR for warfarin users. People taking antihypertensive or glucose-lowering drugs also record baseline home pressure or glucose patterns.

Ongoing monitoring follows a fixed cadence: INR at 1 and 2 weeks (warfarin users only), home blood pressure at 2, 4 and 8 weeks, lipids and liver enzymes at 6–8 weeks, then every 6–12 months while use continues. Success is defined as stable LDL and ApoB (a rise under 10%) together with the targeted benefit, such as lower home blood pressure or improved ALT; a sustained LDL rise above 10% marks the principal risk.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
LDL cholesterol	<100 mg/dL (<70 mg/dL at high cardiovascular risk)	Main known risk	Fasting preferred; baseline and 6–8 weeks; conventional labs often accept <130 mg/dL
ApoB	<80 mg/dL (≤60 mg/dL at high risk)	Particle-level lipid risk	Pair with LDL; conventional labs often flag only >130 mg/dL
Blood pressure	<120/80 mmHg	Benefit and low-pressure risk	Seated home readings, morning and evening; conventional high-pressure threshold ≥130/80 mmHg
ALT	<25 U/L	Liver signal	Pair with GGT; conventional upper limits often 40–55 U/L
GGT	<25 U/L	Liver signal	Morning, fasting; conventional upper limits often 50–60 U/L
Fasting glucose	75–90 mg/dL	Glucose interplay	8–12 hour fast; conventional normal 70–99 mg/dL
HbA1c	<5.4%	Longer-term glucose	Pair with fasting glucose; conventional normal <5.7%
INR (warfarin users only)	Prescriber’s target, usually 2.0–3.0	CYP2C9 interaction	Baseline, then 1 and 2 weeks after starting
hs-CRP	<1.0 mg/L	Inflammation claims	hs-CRP (high-sensitivity C-reactive protein, a general inflammation marker); avoid testing during acute illness; conventional <3.0 mg/L
Whole-blood NAD+	No established target; track change from own baseline	NRPT response	Specialty test; relevant only to NRPT use; about 40% rise expected at standard dose

Qualitative markers:

Digestive comfort (nausea, indigestion, bloating)
Dizziness or light-headedness on standing
Appetite and body weight
Energy levels and exercise recovery
Sleep quality and, for women in the menopause transition, hot-flash frequency
Cognitive clarity and mood

Emerging Research

NO-ALS trial: Randomized trial of EH301 at two doses versus placebo in 380 people with ALS, primary endpoint function-score progression (NCT04562831), with a 300-person extension (NCT05095571); active, not recruiting. Results could confirm or refute the Elysium-supported pilot (de la Rubia 2019).
EH301 with N-acetylcysteine in ALS: Phase 1/2 randomized trial combining EH301, N-acetylcysteine (an antioxidant precursor) and riluzole (a standard ALS drug) in 90 people with ALS, primary endpoint function-score change (NCT07414212); recruiting.
Kidney protection around surgery: Mayo Clinic phase 2 RCT of NRPT (1,000 mg nicotinamide riboside plus 200 mg pterostilbene daily, from 2 weeks before to 6 weeks after surgery) in 54 patients, primary endpoint acute kidney injury (NCT04342975); completed, results not yet posted.
Bone-marrow disorders: Non-randomized phase 2 trial of nicotinamide riboside plus pterostilbene in 10 people with myelodysplastic syndrome (a bone-marrow failure disorder) or clonal cytopenia (unexplained low blood counts), primary endpoint blood-count improvement (NCT07579429); recruiting.
Improved formulations: Eurecat compared a pterostilbene cocrystal with the free form in small bioavailability studies (NCT05561075; NCT06289140) and is testing a cocrystal, silybin (a milk-thistle compound) and nicotinamide riboside blend on exercise-induced malondialdehyde, an oxidative-damage marker, in 14 people (NCT07024966).
Weakening signal, cancer: City of Hope’s phase 2 RCT adding 100 mg pterostilbene twice daily to megestrol in 44 women before hysterectomy found no difference in tumor Ki-67 change (−26.7% versus −25.7%) (NCT03671811), tempering expectations built on cell and animal studies.
Weakening signal, cholesterol: A larger independent trial measuring ApoB would test whether the LDL rise (Riche 2014) offsets the blood-pressure benefit; the rise was highlighted by ChromaDex-affiliated authors (Brenner & Boileau 2019), whose company sells nicotinamide riboside without pterostilbene.
Strengthening signal, liver: Elysium-funded NAFLD enzyme reductions (Dellinger 2023) and ALT falls in healthy older adults (Dellinger 2017) point to a liver research direction; a pterostilbene-only arm would show whether it, rather than nicotinamide riboside, drives these effects.
Human absorption and clearance data: No human half-life or dose–exposure curve has been published. A Kewpie-supported pilot (10 or 100 mg/day for 12 weeks in 30 men) reported microRNA (small gene-regulating RNA) changes and no adverse events (Otsuka 2025); dedicated absorption and clearance studies would anchor dosing.

Conclusion

Pterostilbene is a berry-derived relative of resveratrol whose clearest advantage is better absorption. For health-focused adults, the human evidence is thin: a few short trials of the compound alone, plus several trials pairing it with a vitamin B3 form, in which its own contribution cannot be separated.

The most direct human benefit signal is a modest drop in blood pressure at the higher tested dose. Weaker hints for liver health, menopause-related symptoms and a rare nerve disease come from combination studies. The broader promise of protecting the aging brain, preventing cancer and extending life rests on laboratory and animal research, and early testing in people with cancer has not shown an added effect.

The most consistent risk signal is a rise in “bad” cholesterol at commonly sold doses, most apparent in people with high cholesterol not taking cholesterol-lowering medication. Digestive effects are mostly mild. Laboratory work points to possible interactions with blood thinners and other medications cleared by the same liver enzymes, untested in people.

The evidence base is small, short and heavily tied to industry: the maker of the leading combination product funded most combination trials, a rival company supplied the key single-compound trial and its affiliated researchers highlighted the cholesterol finding, an extract maker ran its own safety study, and Life Extension promotes pairing it with resveratrol while selling both. Pterostilbene is well tolerated, with a believable biological basis, a cholesterol downside clearest in one trial, and a benefit case resting mainly on laboratory and animal work.

Top - Benefits - Risks - Protocol

Pterostilbene for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Medium 🟩 🟩

Blood Pressure Reduction

Low 🟩

Liver Enzyme Improvement

Menopause-Transition Symptom Relief

Slower ALS Progression ⭕️ Not Central to Health & Longevity

Modest Weight Reduction

Blood Sugar Control

Speculative 🟨

Cognitive Protection in Aging

Lifespan Extension

Cancer Prevention

Cellular Energy and Sirtuin Support

Inflammation and Immune Balance

Anxiety Reduction

Skin Protection from Sun Damage

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Medium 🟥 🟥

LDL Cholesterol Increase

Gastrointestinal Discomfort

Low 🟥

Increased Appetite and Weight Gain

Speculative 🟨

Drug Interactions via Liver-Enzyme Inhibition

Excess Blood Pressure Lowering with Antihypertensives

Low Blood Sugar with Diabetes Drugs

Hormone-Sensitive Tissue Effects

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion